We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




NorthStar to Build New Production Line of Medical Radioisotopes

By MedImaging International staff writers
Posted on 09 Jun 2016
Print article
Image: The University of Missouri Research Reactor (MIRR) (Photo courtesy of the University of Missouri).
Image: The University of Missouri Research Reactor (MIRR) (Photo courtesy of the University of Missouri).
NorthStar Medical Radioisotopes (Madison, WI, USA) will construct a new filling line that will quadruple the company’s capacity to dispense molybdenum-99 (Mo-99).

The new high-capacity medical radioisotope filling line will be installed at the University of Missouri Research Reactor (MURR; Columbia, MO, USA) by Von Gahlen International (Zevenaar, The Netherlands). The system will include a high-capacity DPharm unit to fill source vessels quickly, along with companion nuclear radiation containment chambers. The vessels will then be shipped to customers for use with the RadioGenix isotope separation system.

In addition to significantly increasing dispensing capacity at MURR, the new filling line will also be able to prepare source vessels containing Mo-99 generated from natural or enriched molybdenum-98 (Mo-98) targets, which have higher concentrations of Mo-98 and produce approximately three times more Mo-99 than natural targets. Installation is scheduled to begin in November 2106, with full operability targeted for the first half of 2017.

Mo-99 is the parent isotope of technetium-99m, the most widely used radioisotope in medical diagnostic imaging. Because of its unstable nature, Mo-99 does not occur naturally, and is traditionally produced using highly enriched uranium (HEU) in aging nuclear reactors, creating safety and national security concerns and the risk of product shortages. NorthStar is investing more than USD three million in the development of new processes for producing Mo-99 without the use of HEU.

It is striving to become the first producer of Mo-99 in the United States after more than 25 years, while facing competition from SHINE Medical Technologies (SHINE; Monona, WI, USA), which is also developing an alternative production method involving bombarding a low enriched uranium (LEU) uranyl sulfate solution with fast neutrons at the linear accelerator at Argonne National Laboratory (ANL; Lemont, IL, USA).

Related Links:
NorthStar Medical Radioisotopes
University of Missouri Research Reactor
Von Gahlen International
SHINE Medical Technologies
Argonne National Laboratory
Portable Color Doppler Ultrasound System
S5000
Ultrasound Table
Women’s Ultrasound EA Table
Ultrasonic Pocket Doppler
SD1
40/80-Slice CT System
uCT 528

Print article

Channels

MRI

view channel
Image: The AI tool can help interpret and assess how well treatments are working for MS patients (Photo courtesy of Shutterstock)

AI Tool Tracks Effectiveness of Multiple Sclerosis Treatments Using Brain MRI Scans

Multiple sclerosis (MS) is a condition in which the immune system attacks the brain and spinal cord, leading to impairments in movement, sensation, and cognition. Magnetic Resonance Imaging (MRI) markers... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.